Recent Activity

Loading...

VERA

Vera Therapeutics, Inc. Class A · NASDAQ

Performance

-2.22%

1W

-2.77%

1M

-9.94%

3M

+213.09%

6M

+169.12%

YTD

+445.32%

1Y

Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Investment Analysis Report: VERA

Overview

VERA is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has shown significant growth in its financial metrics over the past three years, with an increasing market capitalization and total assets. In this report, we will conduct a comprehensive ...

See more ...

Technical Analysis of VERA 2024-05-10

Overview:

In analyzing the provided VERA TA data for the last 5 days, we will delve into the technical indicators across trend, momentum, volatility, and volume to derive insights into the possible future stock price movement. By examining these indicators comprehensively, we aim to provide a well-informed prediction backed by data-driven analys...

See more ...

Recent News & Updates